On the latest episode of Chasing Life, Dr. Sanjay Gupta explores the impact of the U.S. governments proposal to reschedule cannabis to a Schedule III drug on research. What does it mean? Why now? Could it lead to significant advancements in medical research? Dr. Staci Gruber, our "pot doc", joins the podcast to answer some of his questions.
Listen here.
"I think the first and maybe the biggest thing about the potential rescheduling of cannabis from Schedule I to III is the acknowledgment that there is some medical value... I think there's a lot of misconception about what the rescheduling means and what it changes for consumers and patients, as well as people like me versus industry stakeholders."
~ Dr. Staci Gruber
Comentarios